A therapeutic vaccine using Salmonella-modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma

Leuk Res. 2013 Mar;37(3):341-8. doi: 10.1016/j.leukres.2012.10.003. Epub 2012 Oct 26.

Abstract

Therapeutic vaccination holds potential as complementary treatment for non-Hodgkin's lymphoma (NHL). B-NHL cells are antigen-presenting cells, but they cannot elicit proper antitumor responses because they lack expression of co-stimulatory molecules. Here, we report a novel approach to design improved whole tumor cell vaccines for B-NHL. We demonstrated that Salmonella infection significantly up-regulates CD80, CD86, CD40 and MHC II expression in lymphoma cells, and that therapeutic vaccination with infected and then irradiated lymphoma cells combined with IL-2 elicits strong anti-tumor specific immunity and extended survival in lymphoma-bearing mice. This may represent the basis of an effective immunotherapy against B-NHL that could be easily translated into the clinics.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer Vaccines / chemistry
  • Cancer Vaccines / therapeutic use*
  • Cells, Cultured
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunity, Active / drug effects*
  • Interleukin-2 / pharmacology
  • Interleukin-2 / therapeutic use*
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphoma, B-Cell / complications
  • Lymphoma, B-Cell / immunology
  • Lymphoma, B-Cell / pathology*
  • Lymphoma, B-Cell / therapy*
  • Mice
  • Mice, Inbred BALB C
  • Salmonella / immunology
  • Salmonella Infections / complications
  • Salmonella Infections / immunology
  • Salmonella Infections / pathology*
  • Up-Regulation / drug effects
  • Up-Regulation / immunology

Substances

  • Cancer Vaccines
  • Interleukin-2